Enterprise Therapeutics Close 29 Million In Series B Round
Enterprise Therapeutics have reason to celebrate this week after successfully closing a £29 million Series B funding round.Read more
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
The founders of Enterprise Therapeutics are employees of the University of Sussex and have an agreement in place with the University for the provision of research facilities.